Clinical reference Biomarker Directory
Back to directory

C-X-C Motif Chemokine 9

Emerging

CXCL9 supports HLH/MAS diagnosis as part of an interferon-gamma-driven inflammatory marker panel, alongside CXCL10 and IL-18.

Also known as CXCL9 MIG monokine induced by gamma interferon
In plain language

CXCL9 is very similar to CXCL10 (discussed elsewhere in this set) and is part of the same emerging panel of tests used to recognize a dangerous immune overactivation condition called HLH, especially when combined with a related interleukin marker for extra accuracy.

Biomarker & context

CXCL9 (MIG) is an interferon-gamma-induced chemokine, closely related to CXCL10, that recruits activated T-cells to sites of inflammation.

What it indicates

As referenced in the HLH discussion earlier, CXCL9 is now included alongside ferritin and soluble CD25 among the inflammatory markers used to support an HLH/macrophage activation syndrome diagnosis in current practice, reflecting the same interferon-gamma-driven pathway as CXCL10.

Diagnosis & clinical testing

Measured via serum immunoassay as part of a broader HLH/MAS-suspicious cytokine panel; the IL-18/CXCL9 ratio specifically has been studied as a refinement for improving diagnostic accuracy in distinguishing HLH/MAS from sepsis or other cytokine storm mimics.

Guiding treatment

Elevated CXCL9, especially in combination with the other markers in this evolving panel (ferritin, soluble CD25, IL-18, CXCL10), supports more confident HLH/MAS diagnosis and can influence the decision to escalate to HLH-directed therapy.

Clinical significance

The IL-18/CXCL9 ratio specifically improves diagnostic accuracy for distinguishing HLH/MAS from other causes of cytokine storm.

References
  1. General hematology/immunology reference literature on CXCL9 in HLH/MAS diagnostic panels.